Expression of cyclooxygenase-2 in gastric cancer and its relation to liver metastasis and long-term prognosis

Abstract Background Recent studies have shown that mixed predominantly differentiated-type (MD) early gastric cancer (EGC) might have more malignant potential than pure differentiated-type (PD) EGC. However, no study has analyzed all differentiated-type EGC cases treated endoscopically and surgically. This study aimed to compare the differences in clinicopathological features and long-term prognosis between MD- and PD-EGC. Methods We evaluated all patients with differentiated-type EGCs who were treated endoscopically and surgically in our hospital between January 2010 and October 2014. The clinicopathological features and long-term prognosis of MD-EGC were compared with those of PD-EGC. Results A total of 459 patients with 459 lesions were evaluated in this study; of them, 409 (89.1%) and 50 (10.9%) were classified into the PD and MD groups, respectively. Submucosal invasion was found in 96 (23.5%) patients of the PD group and in 33 (66.0%) patients of the MD group (p < 0.01). The rates of positive lymphatic and vascular invasion and ulceration were significantly higher in the MD group than in the PD group (p < 0.01). The proportion of patients with lymph node metastasis was also significantly higher in the MD group than in the PD group (5 (10%) vs 6 (1.5%), p < 0.01). The 5-year overall and EGC-specific survival rates in the PD group were 88.3 and 99.5%, respectively, while they were 94.0 and 98.0% in the MD group, respectively. Conclusions MD-EGC has more malignant potential than PD-EGC. However, the long-term prognosis of MD-EGC is good and is not significantly different from that of PD-EGC when treated appropriately.

Download Full-text

A case of repeat hepatectomy for liver metastasis from solid pseudopapillary neoplasm of the pancreas: a case report

Surgical Case Reports ◽

10.1186/s40792-021-01134-6 ◽

2021 ◽

Vol 7 (1) ◽

Author(s):

Atsushi Morito ◽

Kojiro Eto ◽

Kozue Matsuishi ◽

Hirokazu Hamasaki ◽

Keisuke Morita ◽

...

Keyword(s):

Liver Metastasis ◽

Liver Metastases ◽

Distal Pancreatectomy ◽

Treatment Guidelines ◽

Histopathological Examination ◽

Repeat Hepatectomy ◽

R0 Resection ◽

Solid Pseudopapillary Neoplasm ◽

Long Term Prognosis

Abstract Background Solid pseudopapillary neoplasm of the pancreas is a rare tumor in young women, metastasizing in only 5–15% of cases, and most commonly to the liver. Although treatment guidelines have not been established, surgical resection is usually performed. We report a rare case of repeat hepatectomy for liver metastases after distal pancreatectomy with solid pseudopapillary neoplasm. Case presentation The patient was a 71-year-old woman who underwent distal pancreatectomy for solid pseudopapillary neoplasm, and liver metastasis occurred 4 years after the first surgery. Partial liver resection was performed for four liver metastases, and histopathological examination revealed a diagnosis of liver metastasis from solid pseudopapillary neoplasm. However, 18 months later, liver metastases were detected again; three tumors were identified, and partial resection was performed, which has provided 18 months’ recurrence-free survival. Conclusions Long-term prognosis can be expected following R0 resection for resectable liver metastasis from solid pseudopapillary neoplasm.

Download Full-text

A case of long-term complete response obtained by combination therapy with anticancer drugs and a dendric cell vaccine for gastric cancer with multiple liver metastasis

Progress of Digestive Endoscopy ◽

10.11641/pde.95.1_56 ◽

2019 ◽

Vol 95 (1) ◽

pp. 56-58

Author(s):

Haruka Yagishita ◽

Naoto Kurihara ◽

Yasuhiro Sasaki ◽

Hideshi Matsuda ◽

Yusuke Asada ◽

...

Keyword(s):

Gastric Cancer ◽

Liver Metastasis ◽

Combination Therapy ◽

Anticancer Drugs ◽

Complete Response ◽

Cell Vaccine ◽

Multiple Liver Metastasis

Download Full-text

Relationship between complications and long-term prognosis after total gastrectomy with splenectomy for proximal advanced gastric cancer

European Journal of Surgical Oncology ◽

10.1016/j.ejso.2018.05.023 ◽

2019 ◽

Vol 45 (11) ◽

pp. 2230

Author(s):

Bing Quan ◽

Wen-Tao Yan ◽

Jiong-Jie Yu ◽

Feng Shen ◽

Tian Yang

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Total Gastrectomy ◽

Long Term Prognosis

Download Full-text

Which Nutritional Scoring System Is More Suitable for Evaluating the Short- or Long-Term Prognosis of Patients with Gastric Cancer Who Underwent Radical Gastrectomy?

Journal of Gastrointestinal Surgery ◽

10.1007/s11605-019-04360-4 ◽

2019 ◽

Vol 24 (9) ◽

pp. 1969-1977 ◽

Cited By ~ 2

Author(s):

Jian-Xian Lin ◽

Li-Zhen Lin ◽

Yi-Hui Tang ◽

Jia-Bin Wang ◽

Jun Lu ◽

...

Keyword(s):

Gastric Cancer ◽

Scoring System ◽

Radical Gastrectomy ◽

Long Term Prognosis

Download Full-text

Radiofrequency ablation versus traditional liver resection and chemotherapy for liver metastases from gastric cancer

Journal of International Medical Research ◽

10.1177/0300060520940509 ◽

2020 ◽

Vol 48 (7) ◽

pp. 030006052094050

Author(s):

Kezhong Tang ◽

Bo Zhang ◽

Linping Dong ◽

Lantian Wang ◽

Zhe Tang

Keyword(s):

Gastric Cancer ◽

Radiofrequency Ablation ◽

Liver Resection ◽

Liver Metastasis ◽

Liver Metastases ◽

Statistical Significance ◽

Local Treatment ◽

Long Term Outcomes ◽

Short And Long Term

Objective To compare the short- and long-term outcomes of radiofrequency ablation (RFA) versus liver resection and chemotherapy for liver metastases from gastric cancer. Methods We retrospectively evaluated 50 patients who underwent curative gastrectomy and local treatments for liver metastases (RFA, n = 20; liver resection, n = 20; and chemotherapy, n = 10) from 2008 to 2018. Results The short- and long-term outcomes of each local treatment were evaluated. The median overall survival (OS) after RFA was similar to that after liver resection (20 vs. 20 months, respectively) and longer than that after chemotherapy (20 vs. 10 months, respectively). The 3-year OS and progression-free survival (PFS) rates after RFA were 20% and 10%, respectively, while those in the liver resection group were 23.5% and 23.5%, respectively. The 3-year OS rate after chemotherapy was 10%. The size and number of metastases were prognostic factors for patients with gastric cancer with liver metastasis without statistical significance. Conclusions Among patients with liver metastasis from gastric cancer, OS and PFS were satisfactory and comparable between RFA and liver resection but better than those of chemotherapy. RFA is an appropriate option for patients with gastric cancer who have a solitary liver metastasis measuring ≤3.0 cm.

Download Full-text